These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
    Author: Vigna E, De Vivo A, Gentile M, Morelli R, Lucia E, Mazzone C, Recchia AG, Vianelli N, Morabito F.
    Journal: Transpl Infect Dis; 2010 Oct; 12(5):428-31. PubMed ID: 20534035.
    Abstract:
    Leishmaniasis is a zoonosis caused by a protozoan of the Leishmania genus. First-line treatment for all forms is currently represented by the use of antimony derivatives, although toxic effects and the number of resistant strains in both immunocompromised and immunocompetent patients is increasing. Liposomal amphotericin B (L-AMB) is less toxic, more effective, and better tolerated, especially in human immunodeficiency virus-negative immunocompromised patients. We present 2 cases of transplanted patients affected by visceral leishmaniasis treated successfully with L-AMB.
    [Abstract] [Full Text] [Related] [New Search]